Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,24825491,polydispersity index (PDI),The polydispersity index (PDI) was 0.12 ± 0.05 and the zeta potential was -33.2 ± 1.4 mV.,"Enhanced oral bioavailability of salmeterol by loaded PLGA microspheres: preparation, in vitro, and in vivo evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24825491/),,0.12,39019,DB00938,Salmeterol
,24825491,zeta potential,The polydispersity index (PDI) was 0.12 ± 0.05 and the zeta potential was -33.2 ± 1.4 mV.,"Enhanced oral bioavailability of salmeterol by loaded PLGA microspheres: preparation, in vitro, and in vivo evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24825491/),mv,-,39020,DB00938,Salmeterol
,24825491,zeta potential,The polydispersity index (PDI) was 0.12 ± 0.05 and the zeta potential was -33.2 ± 1.4 mV.,"Enhanced oral bioavailability of salmeterol by loaded PLGA microspheres: preparation, in vitro, and in vivo evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24825491/),mv,33.2,39021,DB00938,Salmeterol
,28374512,RL,The estimated RL value was 13% suggesting a high gut deposition of inhaled salmeterol.,Pharmacokinetic analysis of inhaled salmeterol in asthma patients: Evidence from two dry powder inhalers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28374512/),%,13,45602,DB00938,Salmeterol
,29493402,time to maximum concentration (tmax),Median salmeterol time to maximum concentration (tmax) was 4.0 minutes.,Pharmacokinetics of Salmeterol and Fluticasone Propionate Delivered in Combination via Easyhaler and Diskus Dry Powder Inhalers in Healthy Subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29493402/),min,4.0,60836,DB00938,Salmeterol
,29493402,tmax,Median fluticasone propionate tmax was from 1.5 to 2.0 hours.,Pharmacokinetics of Salmeterol and Fluticasone Propionate Delivered in Combination via Easyhaler and Diskus Dry Powder Inhalers in Healthy Subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29493402/),h,1.5 to 2.0,60837,DB00938,Salmeterol
,29493402,Terminal elimination half-life,Terminal elimination half-life was 11 hours for salmeterol and 9-10 hours for fluticasone propionate.,Pharmacokinetics of Salmeterol and Fluticasone Propionate Delivered in Combination via Easyhaler and Diskus Dry Powder Inhalers in Healthy Subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29493402/),h,11,60838,DB00938,Salmeterol
,29493402,Terminal elimination half-life,Terminal elimination half-life was 11 hours for salmeterol and 9-10 hours for fluticasone propionate.,Pharmacokinetics of Salmeterol and Fluticasone Propionate Delivered in Combination via Easyhaler and Diskus Dry Powder Inhalers in Healthy Subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29493402/),h,9-10,60839,DB00938,Salmeterol
,12072587,rate-pressure product,"Salmeterol increased mean rate-pressure product by 5% (salmeterol 8878 +/- 1560 vs. placebo 8414 +/- 1440 bpm x mm Hg, p = 0.04), although no increase in plasma norepinephrine, epinephrine, plasma renin activity or ventricular ectopy was detected.",Chronically inhaled salmeterol improves pulmonary function in heart failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12072587/),bpm·hg·mm,8878,61872,DB00938,Salmeterol
,12072587,rate-pressure product,"Salmeterol increased mean rate-pressure product by 5% (salmeterol 8878 +/- 1560 vs. placebo 8414 +/- 1440 bpm x mm Hg, p = 0.04), although no increase in plasma norepinephrine, epinephrine, plasma renin activity or ventricular ectopy was detected.",Chronically inhaled salmeterol improves pulmonary function in heart failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12072587/),bpm·hg·mm,8414,61873,DB00938,Salmeterol
,12072587,Tmax,"The Tmax, Cmax, and half-life of salmeterol at steady-state were 5 min, 715 pg/ml and 11.4 hours, respectively.",Chronically inhaled salmeterol improves pulmonary function in heart failure. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12072587/),min,5,61874,DB00938,Salmeterol
,12072587,Cmax,"The Tmax, Cmax, and half-life of salmeterol at steady-state were 5 min, 715 pg/ml and 11.4 hours, respectively.",Chronically inhaled salmeterol improves pulmonary function in heart failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12072587/),[pg] / [ml],715,61875,DB00938,Salmeterol
,12072587,half-life,"The Tmax, Cmax, and half-life of salmeterol at steady-state were 5 min, 715 pg/ml and 11.4 hours, respectively.",Chronically inhaled salmeterol improves pulmonary function in heart failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12072587/),h,11.4,61876,DB00938,Salmeterol
,33210444,maximum urine concentrations,"Mean ± SD maximum urine concentrations of salmeterol unadjusted for specific gravity reached 4.0 ± 1.6, 2.1 ± 1.5, and 2.2 ± 1.1 ng × ml-1 for 400 μg, 200 μg, and seven consecutive days of 200 μg, respectively, with corresponding maximum urine concentrations of α-hydroxysalmeterol being 11.6 ± 6.1, 5.7 ± 4.6, and 6.5 ± 2.6 ng × ml-1 .",Pharmacokinetics of salmeterol and its main metabolite α-hydroxysalmeterol after acute and chronic dry powder inhalation in exercising endurance-trained men: Implications for doping control. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33210444/),[ng] / [ml],4.0,94365,DB00938,Salmeterol
,33210444,maximum urine concentrations,"Mean ± SD maximum urine concentrations of salmeterol unadjusted for specific gravity reached 4.0 ± 1.6, 2.1 ± 1.5, and 2.2 ± 1.1 ng × ml-1 for 400 μg, 200 μg, and seven consecutive days of 200 μg, respectively, with corresponding maximum urine concentrations of α-hydroxysalmeterol being 11.6 ± 6.1, 5.7 ± 4.6, and 6.5 ± 2.6 ng × ml-1 .",Pharmacokinetics of salmeterol and its main metabolite α-hydroxysalmeterol after acute and chronic dry powder inhalation in exercising endurance-trained men: Implications for doping control. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33210444/),[ng] / [ml],2.1,94366,DB00938,Salmeterol
,33210444,maximum urine concentrations,"Mean ± SD maximum urine concentrations of salmeterol unadjusted for specific gravity reached 4.0 ± 1.6, 2.1 ± 1.5, and 2.2 ± 1.1 ng × ml-1 for 400 μg, 200 μg, and seven consecutive days of 200 μg, respectively, with corresponding maximum urine concentrations of α-hydroxysalmeterol being 11.6 ± 6.1, 5.7 ± 4.6, and 6.5 ± 2.6 ng × ml-1 .",Pharmacokinetics of salmeterol and its main metabolite α-hydroxysalmeterol after acute and chronic dry powder inhalation in exercising endurance-trained men: Implications for doping control. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33210444/),[ng] / [ml],2.2,94367,DB00938,Salmeterol
,33210444,maximum urine concentrations,"Mean ± SD maximum urine concentrations of salmeterol unadjusted for specific gravity reached 4.0 ± 1.6, 2.1 ± 1.5, and 2.2 ± 1.1 ng × ml-1 for 400 μg, 200 μg, and seven consecutive days of 200 μg, respectively, with corresponding maximum urine concentrations of α-hydroxysalmeterol being 11.6 ± 6.1, 5.7 ± 4.6, and 6.5 ± 2.6 ng × ml-1 .",Pharmacokinetics of salmeterol and its main metabolite α-hydroxysalmeterol after acute and chronic dry powder inhalation in exercising endurance-trained men: Implications for doping control. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33210444/),[ng] / [ml],11.6,94368,DB00938,Salmeterol
,33210444,maximum urine concentrations,"Mean ± SD maximum urine concentrations of salmeterol unadjusted for specific gravity reached 4.0 ± 1.6, 2.1 ± 1.5, and 2.2 ± 1.1 ng × ml-1 for 400 μg, 200 μg, and seven consecutive days of 200 μg, respectively, with corresponding maximum urine concentrations of α-hydroxysalmeterol being 11.6 ± 6.1, 5.7 ± 4.6, and 6.5 ± 2.6 ng × ml-1 .",Pharmacokinetics of salmeterol and its main metabolite α-hydroxysalmeterol after acute and chronic dry powder inhalation in exercising endurance-trained men: Implications for doping control. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33210444/),[ng] / [ml],5.7,94369,DB00938,Salmeterol
,33210444,maximum urine concentrations,"Mean ± SD maximum urine concentrations of salmeterol unadjusted for specific gravity reached 4.0 ± 1.6, 2.1 ± 1.5, and 2.2 ± 1.1 ng × ml-1 for 400 μg, 200 μg, and seven consecutive days of 200 μg, respectively, with corresponding maximum urine concentrations of α-hydroxysalmeterol being 11.6 ± 6.1, 5.7 ± 4.6, and 6.5 ± 2.6 ng × ml-1 .",Pharmacokinetics of salmeterol and its main metabolite α-hydroxysalmeterol after acute and chronic dry powder inhalation in exercising endurance-trained men: Implications for doping control. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33210444/),[ng] / [ml],6.5,94370,DB00938,Salmeterol
,10516540,reversibility,"In a double-blind, randomized, crossover and placebo-controlled study design, the respiratory functions of 22 patients (mean age 57.3+/-5.4 years) having mild to severe COPD (5 mild, 8 moderate and 9 severe) and partially reversible airway obstruction [mean baseline reversibility of forced expiratory volume in 1 s (FEV(1)) 19.3+/-3.1%] were evaluated after inhalation of 12 microg formoterol and 50 microg salmeterol.","Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: A crossover, placebo-controlled comparison of onset and duration of action. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10516540/),%,19.3,95418,DB00938,Salmeterol
,10516540,peak bronchodilator effects,"The peak bronchodilator effects occurring at 60 and 120 min following formoterol (0.39 liters) and salmeterol (0.40 liters) inhalation, respectively, were significantly higher than the corresponding levels of placebo (0.02 and -0.12 liters, respectively).","Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: A crossover, placebo-controlled comparison of onset and duration of action. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10516540/),l,0.39,95419,DB00938,Salmeterol
,10516540,peak bronchodilator effects,"The peak bronchodilator effects occurring at 60 and 120 min following formoterol (0.39 liters) and salmeterol (0.40 liters) inhalation, respectively, were significantly higher than the corresponding levels of placebo (0.02 and -0.12 liters, respectively).","Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: A crossover, placebo-controlled comparison of onset and duration of action. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10516540/),l,0.40,95420,DB00938,Salmeterol
,10516540,peak bronchodilator effects,"The peak bronchodilator effects occurring at 60 and 120 min following formoterol (0.39 liters) and salmeterol (0.40 liters) inhalation, respectively, were significantly higher than the corresponding levels of placebo (0.02 and -0.12 liters, respectively).","Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: A crossover, placebo-controlled comparison of onset and duration of action. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10516540/),l,0.02,95421,DB00938,Salmeterol
,10516540,peak bronchodilator effects,"The peak bronchodilator effects occurring at 60 and 120 min following formoterol (0.39 liters) and salmeterol (0.40 liters) inhalation, respectively, were significantly higher than the corresponding levels of placebo (0.02 and -0.12 liters, respectively).","Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: A crossover, placebo-controlled comparison of onset and duration of action. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10516540/),l,0.12,95422,DB00938,Salmeterol
,10516540,area under the curve,The area under the curve values of FEV(1) of formoterol (3.5+/-1.3 l.h) and salmeterol (3.2+/-1.2 l x h) averaged over 12 h were comparable and higher than placebo values (1.2+/-0.5 l x h).,"Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: A crossover, placebo-controlled comparison of onset and duration of action. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10516540/),h·l,3.5,95423,DB00938,Salmeterol
,10516540,area under the curve,The area under the curve values of FEV(1) of formoterol (3.5+/-1.3 l.h) and salmeterol (3.2+/-1.2 l x h) averaged over 12 h were comparable and higher than placebo values (1.2+/-0.5 l x h).,"Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: A crossover, placebo-controlled comparison of onset and duration of action. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10516540/),h·l,3.2,95424,DB00938,Salmeterol
,10516540,area under the curve,The area under the curve values of FEV(1) of formoterol (3.5+/-1.3 l.h) and salmeterol (3.2+/-1.2 l x h) averaged over 12 h were comparable and higher than placebo values (1.2+/-0.5 l x h).,"Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: A crossover, placebo-controlled comparison of onset and duration of action. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10516540/),h·l,1.2,95425,DB00938,Salmeterol
,30431426,AUC0-t,"In study 1, in subjects administered FS Spiromax, the mean (standard deviation (SD)) FP AUC0-t and Cmax were 1,622.64 (419.44) pg×h/mL and 151.36 (40.37) pg/mL, respectively, vs. 1,487.52 (341.25) pg×h/mL and 137.57 (33.64) pg/mL with Seretide Accuhaler.",Bioequivalence of fluticasone propionate and salmeterol (FS) given by the FS Spiromax® and Seretide Accuhaler® systems . ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30431426/),[h·pg] / [ml],"1,622.64",98462,DB00938,Salmeterol
,30431426,AUC0-t,"In study 1, in subjects administered FS Spiromax, the mean (standard deviation (SD)) FP AUC0-t and Cmax were 1,622.64 (419.44) pg×h/mL and 151.36 (40.37) pg/mL, respectively, vs. 1,487.52 (341.25) pg×h/mL and 137.57 (33.64) pg/mL with Seretide Accuhaler.",Bioequivalence of fluticasone propionate and salmeterol (FS) given by the FS Spiromax® and Seretide Accuhaler® systems . ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30431426/),[h·pg] / [ml],"1,487.52",98463,DB00938,Salmeterol
,30431426,Cmax,"In study 1, in subjects administered FS Spiromax, the mean (standard deviation (SD)) FP AUC0-t and Cmax were 1,622.64 (419.44) pg×h/mL and 151.36 (40.37) pg/mL, respectively, vs. 1,487.52 (341.25) pg×h/mL and 137.57 (33.64) pg/mL with Seretide Accuhaler.",Bioequivalence of fluticasone propionate and salmeterol (FS) given by the FS Spiromax® and Seretide Accuhaler® systems . ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30431426/),[pg] / [ml],151.36,98464,DB00938,Salmeterol
,30431426,Cmax,"In study 1, in subjects administered FS Spiromax, the mean (standard deviation (SD)) FP AUC0-t and Cmax were 1,622.64 (419.44) pg×h/mL and 151.36 (40.37) pg/mL, respectively, vs. 1,487.52 (341.25) pg×h/mL and 137.57 (33.64) pg/mL with Seretide Accuhaler.",Bioequivalence of fluticasone propionate and salmeterol (FS) given by the FS Spiromax® and Seretide Accuhaler® systems . ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30431426/),[pg] / [ml],137.57,98465,DB00938,Salmeterol
,30431426,AUC0-t,"Mean (SD) SAL AUC0-t and Cmax with FS Spiromax were 408.42 (155.40) pg×h/mL and 269.48 (105.74) pg/mL, respectively, vs. 401.79 (125.32) pg×h/mL and 265.66 (87.28) pg/mL with Seretide Accuhaler.",Bioequivalence of fluticasone propionate and salmeterol (FS) given by the FS Spiromax® and Seretide Accuhaler® systems . ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30431426/),[h·pg] / [ml],408.42,98466,DB00938,Salmeterol
,30431426,AUC0-t,"Mean (SD) SAL AUC0-t and Cmax with FS Spiromax were 408.42 (155.40) pg×h/mL and 269.48 (105.74) pg/mL, respectively, vs. 401.79 (125.32) pg×h/mL and 265.66 (87.28) pg/mL with Seretide Accuhaler.",Bioequivalence of fluticasone propionate and salmeterol (FS) given by the FS Spiromax® and Seretide Accuhaler® systems . ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30431426/),[h·pg] / [ml],401.79,98467,DB00938,Salmeterol
,30431426,Cmax,"Mean (SD) SAL AUC0-t and Cmax with FS Spiromax were 408.42 (155.40) pg×h/mL and 269.48 (105.74) pg/mL, respectively, vs. 401.79 (125.32) pg×h/mL and 265.66 (87.28) pg/mL with Seretide Accuhaler.",Bioequivalence of fluticasone propionate and salmeterol (FS) given by the FS Spiromax® and Seretide Accuhaler® systems . ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30431426/),[pg] / [ml],269.48,98468,DB00938,Salmeterol
,30431426,Cmax,"Mean (SD) SAL AUC0-t and Cmax with FS Spiromax were 408.42 (155.40) pg×h/mL and 269.48 (105.74) pg/mL, respectively, vs. 401.79 (125.32) pg×h/mL and 265.66 (87.28) pg/mL with Seretide Accuhaler.",Bioequivalence of fluticasone propionate and salmeterol (FS) given by the FS Spiromax® and Seretide Accuhaler® systems . ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30431426/),[pg] / [ml],265.66,98469,DB00938,Salmeterol
,27216137,AUC0-12,"FEV1 AUC0-12 was significantly higher with all FS MDPI doses and FS DPI versus Fp MDPI (p < 0.0001), and with FS MDPI 100/50 μg versus FS DPI (least squares [LS] mean, 57.88 mL; p = 0.0017).",Dose-ranging study of salmeterol using a novel fluticasone propionate/salmeterol multidose dry powder inhaler in patients with persistent asthma. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27216137/),ml,57.88,104453,DB00938,Salmeterol
,27216137,AUC0-12,"FEV1 AUC0-12 trended toward higher efficacy with FS MDPI 100/25 μg (LS mean, 34.14 mL; p = 0.0624) and was comparable with FS MDPI 100/12.5 μg (LS mean, 3.42 mL; p = 0.8503) versus FS DPI.",Dose-ranging study of salmeterol using a novel fluticasone propionate/salmeterol multidose dry powder inhaler in patients with persistent asthma. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27216137/),ml,34.14,104454,DB00938,Salmeterol
,27216137,AUC0-12,"FEV1 AUC0-12 trended toward higher efficacy with FS MDPI 100/25 μg (LS mean, 34.14 mL; p = 0.0624) and was comparable with FS MDPI 100/12.5 μg (LS mean, 3.42 mL; p = 0.8503) versus FS DPI.",Dose-ranging study of salmeterol using a novel fluticasone propionate/salmeterol multidose dry powder inhaler in patients with persistent asthma. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27216137/),ml,3.42,104455,DB00938,Salmeterol
,19878590,plasma AUC,"Mean plasma AUC values were lower in COPD patients versus healthy subjects for budesonide (3.07 microM x hr versus 6.21 microM x hr) and fluticasone (0.84 microM x hr versus 1.50 microM x hr), and the dose-adjusted AUC (geometric mean) ratios in healthy subjects and patients with severe COPD for plasma budesonide and fluticasone were similar (2.02 versus 1.80; primary end point).",The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19878590/),h·μM,3.07,136756,DB00938,Salmeterol
,19878590,plasma AUC,"Mean plasma AUC values were lower in COPD patients versus healthy subjects for budesonide (3.07 microM x hr versus 6.21 microM x hr) and fluticasone (0.84 microM x hr versus 1.50 microM x hr), and the dose-adjusted AUC (geometric mean) ratios in healthy subjects and patients with severe COPD for plasma budesonide and fluticasone were similar (2.02 versus 1.80; primary end point).",The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19878590/),h·μM,6.21,136757,DB00938,Salmeterol
,19878590,plasma AUC,"Mean plasma AUC values were lower in COPD patients versus healthy subjects for budesonide (3.07 microM x hr versus 6.21 microM x hr) and fluticasone (0.84 microM x hr versus 1.50 microM x hr), and the dose-adjusted AUC (geometric mean) ratios in healthy subjects and patients with severe COPD for plasma budesonide and fluticasone were similar (2.02 versus 1.80; primary end point).",The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19878590/),h·μM,0.84,136758,DB00938,Salmeterol
,19878590,plasma AUC,"Mean plasma AUC values were lower in COPD patients versus healthy subjects for budesonide (3.07 microM x hr versus 6.21 microM x hr) and fluticasone (0.84 microM x hr versus 1.50 microM x hr), and the dose-adjusted AUC (geometric mean) ratios in healthy subjects and patients with severe COPD for plasma budesonide and fluticasone were similar (2.02 versus 1.80; primary end point).",The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19878590/),h·μM,1.50,136759,DB00938,Salmeterol
,19878590,plasma AUC,"Mean plasma AUC values were lower in COPD patients versus healthy subjects for budesonide (3.07 microM x hr versus 6.21 microM x hr) and fluticasone (0.84 microM x hr versus 1.50 microM x hr), and the dose-adjusted AUC (geometric mean) ratios in healthy subjects and patients with severe COPD for plasma budesonide and fluticasone were similar (2.02 versus 1.80; primary end point).",The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19878590/),,2,136760,DB00938,Salmeterol
,19878590,plasma AUC,"Mean plasma AUC values were lower in COPD patients versus healthy subjects for budesonide (3.07 microM x hr versus 6.21 microM x hr) and fluticasone (0.84 microM x hr versus 1.50 microM x hr), and the dose-adjusted AUC (geometric mean) ratios in healthy subjects and patients with severe COPD for plasma budesonide and fluticasone were similar (2.02 versus 1.80; primary end point).",The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19878590/),,1,136761,DB00938,Salmeterol
,19878590,AU,"Mean plasma AUC values were lower in COPD patients versus healthy subjects for budesonide (3.07 microM x hr versus 6.21 microM x hr) and fluticasone (0.84 microM x hr versus 1.50 microM x hr), and the dose-adjusted AUC (geometric mean) ratios in healthy subjects and patients with severe COPD for plasma budesonide and fluticasone were similar (2.02 versus 1.80; primary end point).",The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19878590/),,2,136762,DB00938,Salmeterol
,19878590,AU,"Mean plasma AUC values were lower in COPD patients versus healthy subjects for budesonide (3.07 microM x hr versus 6.21 microM x hr) and fluticasone (0.84 microM x hr versus 1.50 microM x hr), and the dose-adjusted AUC (geometric mean) ratios in healthy subjects and patients with severe COPD for plasma budesonide and fluticasone were similar (2.02 versus 1.80; primary end point).",The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19878590/),,1,136763,DB00938,Salmeterol
,19878590,Tmax,"In COPD patients, the Tmax and the mean residence time in the systemic circulation were shorter for budesonide versus fluticasone (15.5 min versus 50.8 min and 4.41 hrs versus 12.78 hrs, respectively) and Cmax was higher (1.08 microM versus 0.09 microM).",The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19878590/),min,15.5,136764,DB00938,Salmeterol
,19878590,Tmax,"In COPD patients, the Tmax and the mean residence time in the systemic circulation were shorter for budesonide versus fluticasone (15.5 min versus 50.8 min and 4.41 hrs versus 12.78 hrs, respectively) and Cmax was higher (1.08 microM versus 0.09 microM).",The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19878590/),min,50.8,136765,DB00938,Salmeterol
,19878590,mean residence time,"In COPD patients, the Tmax and the mean residence time in the systemic circulation were shorter for budesonide versus fluticasone (15.5 min versus 50.8 min and 4.41 hrs versus 12.78 hrs, respectively) and Cmax was higher (1.08 microM versus 0.09 microM).",The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19878590/),h,4.41,136766,DB00938,Salmeterol
,19878590,mean residence time,"In COPD patients, the Tmax and the mean residence time in the systemic circulation were shorter for budesonide versus fluticasone (15.5 min versus 50.8 min and 4.41 hrs versus 12.78 hrs, respectively) and Cmax was higher (1.08 microM versus 0.09 microM).",The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19878590/),h,12.78,136767,DB00938,Salmeterol
,19878590,Cmax,"In COPD patients, the Tmax and the mean residence time in the systemic circulation were shorter for budesonide versus fluticasone (15.5 min versus 50.8 min and 4.41 hrs versus 12.78 hrs, respectively) and Cmax was higher (1.08 microM versus 0.09 microM).",The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19878590/),μM,1.08,136768,DB00938,Salmeterol
,19878590,Cmax,"In COPD patients, the Tmax and the mean residence time in the systemic circulation were shorter for budesonide versus fluticasone (15.5 min versus 50.8 min and 4.41 hrs versus 12.78 hrs, respectively) and Cmax was higher (1.08 microM versus 0.09 microM).",The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19878590/),μM,0.09,136769,DB00938,Salmeterol
,28033454,Maximum rac-salmeterol urine concentrations,"Maximum rac-salmeterol urine concentrations were obtained at 2 h for both doses with medians of 0.084 ng/mL after the 50 µg dose and 2.1 ng/mL after the 200 µg dose, with an individual maximum of 5.7 ng/mL.",Enantioselective disposition of (R)-salmeterol and (S)-salmeterol in urine following inhaled dosing and application to doping control. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28033454/),[ng] / [ml],0.084,140351,DB00938,Salmeterol
,28033454,Maximum rac-salmeterol urine concentrations,"Maximum rac-salmeterol urine concentrations were obtained at 2 h for both doses with medians of 0.084 ng/mL after the 50 µg dose and 2.1 ng/mL after the 200 µg dose, with an individual maximum of 5.7 ng/mL.",Enantioselective disposition of (R)-salmeterol and (S)-salmeterol in urine following inhaled dosing and application to doping control. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28033454/),[ng] / [ml],2.1,140352,DB00938,Salmeterol
,28033454,maximum,"Maximum rac-salmeterol urine concentrations were obtained at 2 h for both doses with medians of 0.084 ng/mL after the 50 µg dose and 2.1 ng/mL after the 200 µg dose, with an individual maximum of 5.7 ng/mL.",Enantioselective disposition of (R)-salmeterol and (S)-salmeterol in urine following inhaled dosing and application to doping control. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28033454/),[ng] / [ml],5.7,140353,DB00938,Salmeterol
,7766724,Maximum plasma concentrations,Maximum plasma concentrations attained at 1 h after dosing ranged between 35.3 and 66.8 ng ml-1 and were within the calibration range of the assay.,The determination in human plasma of 1-hydroxy-2-naphthoic acid following administration of salmeterol xinafoate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7766724/),[ng] / [ml],35.3 and 66.8,162911,DB00938,Salmeterol
,32133324,half-lives,"FTS, SM, and TTP rapidly reached maximum plasma concentration after inhalation (0.08-3.00 h, 0.03-0.10 h and 0.03-0.10 h, respectively) and were eliminated with mean half-lives of 9.29-10.44 h, 6.09-12.39 h and 0.25-47.42 h, respectively.","Pharmacokinetic characteristics of fluticasone, salmeterol and tiotropium after concurrent inhalation. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32133324/),h,9.29-10.44,172237,DB00938,Salmeterol
,32133324,half-lives,"FTS, SM, and TTP rapidly reached maximum plasma concentration after inhalation (0.08-3.00 h, 0.03-0.10 h and 0.03-0.10 h, respectively) and were eliminated with mean half-lives of 9.29-10.44 h, 6.09-12.39 h and 0.25-47.42 h, respectively.","Pharmacokinetic characteristics of fluticasone, salmeterol and tiotropium after concurrent inhalation. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32133324/),h,6.09-12.39,172238,DB00938,Salmeterol
,32133324,half-lives,"FTS, SM, and TTP rapidly reached maximum plasma concentration after inhalation (0.08-3.00 h, 0.03-0.10 h and 0.03-0.10 h, respectively) and were eliminated with mean half-lives of 9.29-10.44 h, 6.09-12.39 h and 0.25-47.42 h, respectively.","Pharmacokinetic characteristics of fluticasone, salmeterol and tiotropium after concurrent inhalation. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32133324/),h,0.25-47.42,172239,DB00938,Salmeterol
,10150494,t1/2,HFA134a was rapidly absorbed after inhalation with dose-related blood concentrations which declined rapidly after dosing (t1/2 = 31 min).,Clinical pharmacology of HFA134a. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10150494/),min,31,177153,DB00938,Salmeterol
,19302910,FP,"The only notable differences were mean FP for particle sizes 2.3 to 3.2 microm (21.4 microg/dose for RPID, 25.6 microg/dose for Diskus) and for sizes 4.0 to 6.2 microm (17.3 microg/dose for RPID, 11.7 microg/dose for Diskus).","Pharmacokinetic, pharmacodynamic, efficacy, and safety data from two randomized, double-blind studies in patients with asthma and an in vitro study comparing two dry-powder inhalers delivering a combination of salmeterol 50 microg and fluticasone propionate 250 microg: implications for establishing bioequivalence of inhaled products. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19302910/),,17,181554,DB00938,Salmeterol
,19302910,maximum heart rate,"A small but statistically significant increase in maximum heart rate (5 beats/min) was noted in the RPID group (ratio, 1.05 [95% CI, 1.01 to 1.10]; P = 0.029).","Pharmacokinetic, pharmacodynamic, efficacy, and safety data from two randomized, double-blind studies in patients with asthma and an in vitro study comparing two dry-powder inhalers delivering a combination of salmeterol 50 microg and fluticasone propionate 250 microg: implications for establishing bioequivalence of inhaled products. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19302910/),[beats] / [min],5,181555,DB00938,Salmeterol
,31364911,AUC(0-t),"Estimated AUC(0-t) and Cmax ratios for salmeterol were, respectively, 1.08 (1.04-1.11) and 1.00 (0.94-1.04) for 100/50 μg FP/S, 1.03 (0.99-1.07) and 0.93 (0.87-1.00) for 250/50 μg, and 1.00 (0.96-1.04) and 0.86 (0.81-0.91) for 500/50 μg.",Equivalent Systemic Exposure to Fluticasone Propionate/Salmeterol Following Single Inhaled Doses from Advair Diskus and Wixela Inhub: Results of Three Pharmacokinetic Bioequivalence Studies. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31364911/),,1,186310,DB00938,Salmeterol
,31364911,AUC(0-t),"Estimated AUC(0-t) and Cmax ratios for salmeterol were, respectively, 1.08 (1.04-1.11) and 1.00 (0.94-1.04) for 100/50 μg FP/S, 1.03 (0.99-1.07) and 0.93 (0.87-1.00) for 250/50 μg, and 1.00 (0.96-1.04) and 0.86 (0.81-0.91) for 500/50 μg.",Equivalent Systemic Exposure to Fluticasone Propionate/Salmeterol Following Single Inhaled Doses from Advair Diskus and Wixela Inhub: Results of Three Pharmacokinetic Bioequivalence Studies. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31364911/),,0,186311,DB00938,Salmeterol
,31364911,Cmax ratios,"Estimated AUC(0-t) and Cmax ratios for salmeterol were, respectively, 1.08 (1.04-1.11) and 1.00 (0.94-1.04) for 100/50 μg FP/S, 1.03 (0.99-1.07) and 0.93 (0.87-1.00) for 250/50 μg, and 1.00 (0.96-1.04) and 0.86 (0.81-0.91) for 500/50 μg.",Equivalent Systemic Exposure to Fluticasone Propionate/Salmeterol Following Single Inhaled Doses from Advair Diskus and Wixela Inhub: Results of Three Pharmacokinetic Bioequivalence Studies. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31364911/),,1,186312,DB00938,Salmeterol
,20150524,first-order rate constant,"The FP population PK parameter estimates of the first-order rate constant, relative clearance, and volume of distribution were 4.07 1/h, 890 L/h, and 9800 L, respectively.",Population pharmacokinetics and pharmacodynamics of inhaled ciclesonide and fluticasone propionate in patients with persistent asthma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20150524/),[1] / [h],4.07,187808,DB00938,Salmeterol
,20150524,relative clearance,"The FP population PK parameter estimates of the first-order rate constant, relative clearance, and volume of distribution were 4.07 1/h, 890 L/h, and 9800 L, respectively.",Population pharmacokinetics and pharmacodynamics of inhaled ciclesonide and fluticasone propionate in patients with persistent asthma. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20150524/),[l] / [h],890,187809,DB00938,Salmeterol
,20150524,volume of distribution,"The FP population PK parameter estimates of the first-order rate constant, relative clearance, and volume of distribution were 4.07 1/h, 890 L/h, and 9800 L, respectively.",Population pharmacokinetics and pharmacodynamics of inhaled ciclesonide and fluticasone propionate in patients with persistent asthma. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20150524/),l,9800,187810,DB00938,Salmeterol
,20150524,first-order absorption rate constant,"The Des-CIC PK parameter estimates of the first-order absorption rate constant were 2.63 1/h, clearance 202 L/h (non-CIC treatment) or 271 L/h (CIC treatment), and volume of distribution 947 L.",Population pharmacokinetics and pharmacodynamics of inhaled ciclesonide and fluticasone propionate in patients with persistent asthma. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20150524/),[1] / [h],2.63,187811,DB00938,Salmeterol
,20150524,clearance,"The Des-CIC PK parameter estimates of the first-order absorption rate constant were 2.63 1/h, clearance 202 L/h (non-CIC treatment) or 271 L/h (CIC treatment), and volume of distribution 947 L.",Population pharmacokinetics and pharmacodynamics of inhaled ciclesonide and fluticasone propionate in patients with persistent asthma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20150524/),[l] / [h],202,187812,DB00938,Salmeterol
,20150524,clearance,"The Des-CIC PK parameter estimates of the first-order absorption rate constant were 2.63 1/h, clearance 202 L/h (non-CIC treatment) or 271 L/h (CIC treatment), and volume of distribution 947 L.",Population pharmacokinetics and pharmacodynamics of inhaled ciclesonide and fluticasone propionate in patients with persistent asthma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20150524/),[l] / [h],271,187813,DB00938,Salmeterol
,20150524,volume of distribution,"The Des-CIC PK parameter estimates of the first-order absorption rate constant were 2.63 1/h, clearance 202 L/h (non-CIC treatment) or 271 L/h (CIC treatment), and volume of distribution 947 L.",Population pharmacokinetics and pharmacodynamics of inhaled ciclesonide and fluticasone propionate in patients with persistent asthma. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20150524/),l,947,187814,DB00938,Salmeterol
,20150524,maximum cortisol release rate,"Gender was a significant covariate on the maximum cortisol release rate (male, 3440 µg/h; female, 4310 µg/h).",Population pharmacokinetics and pharmacodynamics of inhaled ciclesonide and fluticasone propionate in patients with persistent asthma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20150524/),[μg] / [h],3440,187815,DB00938,Salmeterol
,20150524,maximum cortisol release rate,"Gender was a significant covariate on the maximum cortisol release rate (male, 3440 µg/h; female, 4310 µg/h).",Population pharmacokinetics and pharmacodynamics of inhaled ciclesonide and fluticasone propionate in patients with persistent asthma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20150524/),[μg] / [h],4310,187816,DB00938,Salmeterol
,11825095,peak concentration,"In patients who inhaled salmeterol 50microg twice daily for 10 months, a second peak concentration of 0.07 to 0.2 microg/L occurred 45 to 90 minutes after inhalation, probably because of the gastrointestinal absorption of the swallowed drug.",Clinical pharmacokinetics of salmeterol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11825095/),[μg] / [l],0.07 to 0.2,203516,DB00938,Salmeterol
,11825095,elimination half-life,"The xinafoate moiety has no apparent pharmacological activity, is highly protein bound (>99%), largely to albumin, and has a long elimination half-life of about 12 to 15 days in healthy individuals.",Clinical pharmacokinetics of salmeterol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11825095/),d,12 to 15,203517,DB00938,Salmeterol
,11825095,steady-state concentrations,"For this reason, it accumulates in plasma during repeated administration, with steady-state concentrations reaching about 80 to 90 microg/L in patients treated with salmeterol 50microg twice daily for several months.",Clinical pharmacokinetics of salmeterol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11825095/),[μg] / [l],80 to 90,203518,DB00938,Salmeterol
,17632023,area under the curve (AUC),"The values of the area under the curve (AUC) of FEV1, FVC and IC during the administration of tulobuterol were 2.98+/-1.05, 1.81+/-0.98, 0.75+/-0.85 L h, respectively, and during the administration of salmeterol they were 6.39+/-1.12, 6.61+/-1.34, 4.28+/-0.91 L h, respectively.",Comparison of bronchodilatory properties of transdermal and inhaled long-acting beta 2-agonists. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17632023/),h·l,2.98,204217,DB00938,Salmeterol
,17632023,area under the curve (AUC),"The values of the area under the curve (AUC) of FEV1, FVC and IC during the administration of tulobuterol were 2.98+/-1.05, 1.81+/-0.98, 0.75+/-0.85 L h, respectively, and during the administration of salmeterol they were 6.39+/-1.12, 6.61+/-1.34, 4.28+/-0.91 L h, respectively.",Comparison of bronchodilatory properties of transdermal and inhaled long-acting beta 2-agonists. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17632023/),h·l,1.81,204218,DB00938,Salmeterol
,17632023,area under the curve (AUC),"The values of the area under the curve (AUC) of FEV1, FVC and IC during the administration of tulobuterol were 2.98+/-1.05, 1.81+/-0.98, 0.75+/-0.85 L h, respectively, and during the administration of salmeterol they were 6.39+/-1.12, 6.61+/-1.34, 4.28+/-0.91 L h, respectively.",Comparison of bronchodilatory properties of transdermal and inhaled long-acting beta 2-agonists. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17632023/),h·l,0.75,204219,DB00938,Salmeterol
,17632023,area under the curve (AUC),"The values of the area under the curve (AUC) of FEV1, FVC and IC during the administration of tulobuterol were 2.98+/-1.05, 1.81+/-0.98, 0.75+/-0.85 L h, respectively, and during the administration of salmeterol they were 6.39+/-1.12, 6.61+/-1.34, 4.28+/-0.91 L h, respectively.",Comparison of bronchodilatory properties of transdermal and inhaled long-acting beta 2-agonists. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17632023/),h·l,6.39,204220,DB00938,Salmeterol
,17632023,area under the curve (AUC),"The values of the area under the curve (AUC) of FEV1, FVC and IC during the administration of tulobuterol were 2.98+/-1.05, 1.81+/-0.98, 0.75+/-0.85 L h, respectively, and during the administration of salmeterol they were 6.39+/-1.12, 6.61+/-1.34, 4.28+/-0.91 L h, respectively.",Comparison of bronchodilatory properties of transdermal and inhaled long-acting beta 2-agonists. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17632023/),h·l,6.61,204221,DB00938,Salmeterol
,17632023,area under the curve (AUC),"The values of the area under the curve (AUC) of FEV1, FVC and IC during the administration of tulobuterol were 2.98+/-1.05, 1.81+/-0.98, 0.75+/-0.85 L h, respectively, and during the administration of salmeterol they were 6.39+/-1.12, 6.61+/-1.34, 4.28+/-0.91 L h, respectively.",Comparison of bronchodilatory properties of transdermal and inhaled long-acting beta 2-agonists. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17632023/),h·l,4.28,204222,DB00938,Salmeterol
,16179215,FE,"After 12 weeks, the average post-dose FEV1 over 12 h was significantly higher with tiotropium compared with salmeterol (167 vs. 130 mL, respectively, p=0.03), as was peak FEV1 (262 vs. 216 ml, respectively, p=0.01).",Improved daytime spirometric efficacy of tiotropium compared with salmeterol in patients with COPD. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16179215/),ml,167,246316,DB00938,Salmeterol
,16179215,FE,"After 12 weeks, the average post-dose FEV1 over 12 h was significantly higher with tiotropium compared with salmeterol (167 vs. 130 mL, respectively, p=0.03), as was peak FEV1 (262 vs. 216 ml, respectively, p=0.01).",Improved daytime spirometric efficacy of tiotropium compared with salmeterol in patients with COPD. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16179215/),ml,130,246317,DB00938,Salmeterol
,16179215,peak FEV1,"After 12 weeks, the average post-dose FEV1 over 12 h was significantly higher with tiotropium compared with salmeterol (167 vs. 130 mL, respectively, p=0.03), as was peak FEV1 (262 vs. 216 ml, respectively, p=0.01).",Improved daytime spirometric efficacy of tiotropium compared with salmeterol in patients with COPD. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16179215/),ml,262,246318,DB00938,Salmeterol
,16179215,peak FEV1,"After 12 weeks, the average post-dose FEV1 over 12 h was significantly higher with tiotropium compared with salmeterol (167 vs. 130 mL, respectively, p=0.03), as was peak FEV1 (262 vs. 216 ml, respectively, p=0.01).",Improved daytime spirometric efficacy of tiotropium compared with salmeterol in patients with COPD. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16179215/),ml,216,246319,DB00938,Salmeterol
,7905380,plasma t1/2,"The plasma t1/2, after intravenous administration, was 5 hr in rats and 2 hr in dogs.",Disposition of salmeterol xinafoate in laboratory animals and humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7905380/),h,5,260650,DB00938,Salmeterol
,7905380,plasma t1/2,"The plasma t1/2, after intravenous administration, was 5 hr in rats and 2 hr in dogs.",Disposition of salmeterol xinafoate in laboratory animals and humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7905380/),h,2,260651,DB00938,Salmeterol
,7905380,volume of distribution,The volume of distribution of salmeterol was significantly greater than total body water in both rats (40 liters/kg) and dogs (6 liters/kg) and indicated high tissue uptake of the compound.,Disposition of salmeterol xinafoate in laboratory animals and humans. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7905380/),[l] / [kg],40,260652,DB00938,Salmeterol
,7905380,volume of distribution,The volume of distribution of salmeterol was significantly greater than total body water in both rats (40 liters/kg) and dogs (6 liters/kg) and indicated high tissue uptake of the compound.,Disposition of salmeterol xinafoate in laboratory animals and humans. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7905380/),[l] / [kg],6,260653,DB00938,Salmeterol
,7905380,Plasma clearance,Plasma clearance was high in rats (95 ml/min/kg) and dogs (30 ml/min/kg).,Disposition of salmeterol xinafoate in laboratory animals and humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7905380/),[ml] / [kg·min],95,260654,DB00938,Salmeterol
,7905380,Plasma clearance,Plasma clearance was high in rats (95 ml/min/kg) and dogs (30 ml/min/kg).,Disposition of salmeterol xinafoate in laboratory animals and humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7905380/),[ml] / [kg·min],30,260655,DB00938,Salmeterol
,7905380,Biliary excretion,"Biliary excretion in rats and dogs accounted for 53% (0-27 hr) and 40% (0-8 hr) of an oral dose, respectively, indicating good absorption across the gastrointestinal tract.",Disposition of salmeterol xinafoate in laboratory animals and humans. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7905380/),%,53,260656,DB00938,Salmeterol
,7905380,Biliary excretion,"Biliary excretion in rats and dogs accounted for 53% (0-27 hr) and 40% (0-8 hr) of an oral dose, respectively, indicating good absorption across the gastrointestinal tract.",Disposition of salmeterol xinafoate in laboratory animals and humans. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7905380/),%,40,260657,DB00938,Salmeterol
,11294367,pulse rate,"With the exception of a higher pulse rate after repeat administration of salmeterol [66.2 beats per minute (bpm) versus 63.6 bpm], there were no significant differences between the single-dose and repeat-dose salmeterol groups.",Salmeterol and fluticasone propionate given as a combination. Lack of systemic pharmacodynamic and pharmacokinetic interactions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294367/),[beats·min] / [bpm],66.2,273152,DB00938,Salmeterol
,11294367,pulse rate,"With the exception of a higher pulse rate after repeat administration of salmeterol [66.2 beats per minute (bpm) versus 63.6 bpm], there were no significant differences between the single-dose and repeat-dose salmeterol groups.",Salmeterol and fluticasone propionate given as a combination. Lack of systemic pharmacodynamic and pharmacokinetic interactions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294367/),bpm,63.6,273153,DB00938,Salmeterol
,11294367,excretion,"Fluticasone propionate reduced 24-h urinary cortisol excretion (22.4 microg compared with 48.6 microg with placebo), but this was unaffected by the co-administration of salmeterol.",Salmeterol and fluticasone propionate given as a combination. Lack of systemic pharmacodynamic and pharmacokinetic interactions. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294367/),μg,22.4,273154,DB00938,Salmeterol
,11294367,excretion,"Fluticasone propionate reduced 24-h urinary cortisol excretion (22.4 microg compared with 48.6 microg with placebo), but this was unaffected by the co-administration of salmeterol.",Salmeterol and fluticasone propionate given as a combination. Lack of systemic pharmacodynamic and pharmacokinetic interactions. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294367/),μg,48.6,273155,DB00938,Salmeterol
